Robert D. Gibbons

Robert D. Gibbons

Auto-generated profile, based on publicly available information

Robert D. Gibbons

University of Chicago, Chicago, Illinois

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2012 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
RGRobert D. Gibbons
Robert D. Gibbons
CBC. Hendricks Brown
C. Hendricks Brown
KHKwan Hur
Kwan Hur
JDJohn M. Davis
John M. Davis
JMJ. John Mann
J. John Mann
In 2004, the US Food and Drug Administration (FDA) issued a black box warning for antidepressants and risk of suicide in children and adolescents. No actual suicides occurred in these trials with either antidepressant or placebo, so this concern was based primarily on suicide ideation and attempts.1 In 2006, the FDA extended the warning to young adults aged 18 to 25 years.2 The original warning was based on a meta-analysis of adverse event reports (AERs) of suicidal thoughts and behavior from 25 clinical randomized controlled trials (RCTs) conducted by the pharmaceutical companies in pursuit of approval of antidepressant medications. These trials were typically short term and limited to the newer antidepressant classes of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors. Results of the analysis revealed an overall odds ratio (OR) of 1.78 (95% CI, 1.14-2.77), indicating that the rate of suicidal thoughts and behavior from AERs was significantly higher in children randomized to active antidepressant treatment relative to placebo. The extension of the warning to young adults was based on a second meta-analysis of AERs in 372 RCTs in 99 839 adult patients. The FDA found a result that approached significance for young adults aged 18 to 24 years (OR = 1.62; 95% CI, 0.97-2.71) and, in contrast, a significantly decreased risk in adults aged 25 to 64 years (OR = 0.79; 95% CI, 0.64-0.98) and geriatric patients aged 65 years and older (OR = 0.37; 95% CI, 0.18-0.76).

1 November 2012 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
RGRobert D. Gibbons
Robert D. Gibbons
DWDavid J. Weiss
David J. Weiss
PPPaul A. Pilkonis
Paul A. Pilkonis
EFEllen Frank
Ellen Frank
TMTara Moore
Tara Moore
DKDavid J. Kupfer
David J. Kupfer
Imagine a 1000-item mathematics test with items ranging in difficulty from basic arithmetic to advanced calculus. Consider 2 examinees: a fourth grader and a graduate student in mathematics. Most questions will be uninformative for both examinees (too difficult for the first and too easy for the second). To decrease examinee burden, we could create a short test of 10 items, equally spaced along the mathematics difficulty continuum. Although this test would be quick to administer, it would provide imprecise estimates of these 2 examinees' ability because only 1 or 2 items would be appropriate for either examinee. A better approach would be to begin by administering an item of intermediate difficulty and, based on the response scored as correct or incorrect, select the next item at a level of difficulty either lower or higher. This process would continue until the uncertainty in the estimated ability is smaller than a predefined threshold. This process is called computerized adaptive testing (CAT). To use CAT, we must first calibrate a bank of test items using an item response theory (IRT) model that relates properties of the test items (eg, their difficulty and discrimination) to the ability (or other trait) of the examinee. The paradigm shift is that rather than administering a fixed number of items that provide limited information for any given examinee, we adaptively administer a varying number of items that are targeted to the examinee's specific level of ability or impairment. CAT allows us to adaptively select a small set of items for each examinee out of a much larger bank of test items, targeting precision by selecting items based on prior ability, trait, or impairment estimates.

1 June 2012 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
RGRobert D. Gibbons
Robert D. Gibbons
KHKwan Hur
Kwan Hur
CBC. Hendricks Brown
C. Hendricks Brown
JDJohn M. Davis
John M. Davis
JMJ. John Mann
J. John Mann
Recent reports suggest that the efficacy of antidepressant medications compared with placebo may be overstated owing to publication bias1 and that antidepressants have less efficacy for mildly depressed patients.2,3 For example,1 of 74 US Food and Drug Administration–registered randomized controlled trials (RCTs) involving 12 antidepressants in 12 564 patients, 94% of published trials were positive, whereas only 51% of all US Food and Drug Administration–registered studies were positive. A meta-analysis2 of 35 RCTs of 4 antidepressants (fluoxetine hydrochloride, venlafaxine hydrochloride, nefazodone hydrochloride, and paroxetine hydrochloride) found that only studies with higher average baseline severity achieved the putative clinically significant 3-point difference in Hamilton Depression Scale (HAM-D) scores.4 A study3 of individual-level data from 6 RCTs comparing paroxetine or imipramine hydrochloride with placebo concluded that there was benefit only for those with very severe depression.

28 March 2016 in Annual Review of Clinical Psychology
Verified
Journal Article
Closed access
RGRobert D. Gibbons
Robert D. Gibbons
DWDavid J. Weiss
David J. Weiss
EFEllen Frank
Ellen Frank
DKDavid Kupfer
David Kupfer
In this review we explore recent developments in computerized adaptive diagnostic screening and computerized adaptive testing for the presence and severity of mental health disorders such as depression, anxiety, and mania. The statistical methodology is unique in that it is based on multidimensional item response theory (severity) and random forests (diagnosis) instead of traditional mental health measurement based on classical test theory (a simple total score) or unidimensional item response theory. We show that the information contained in large item banks consisting of hundreds of symptom items can be efficiently calibrated using multidimensional item response theory, and the information contained in these large item banks can be precisely extracted using adaptive administration of a small set of items for each individual. In terms of diagnosis, computerized adaptive diagnostic screening can accurately track an hour-long face-to-face clinician diagnostic interview for major depressive disorder (as an example) in less than a minute using an average of four questions with unprecedented high sensitivity and specificity. Directions for future research and applications are discussed.

1 December 2013 in American Journal of Psychiatry
Verified
Journal Article
Closed access
RGRobert D. Gibbons
Robert D. Gibbons
JMJ. John Mann
J. John Mann

9 June 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
PNPeter Nagele
Peter Nagele
BPBen J. Palanca
Ben J. Palanca
BGBritt Gott
Britt Gott
FBFrank Brown
Frank Brown
LBLinda Barnes
Linda Barnes
CCCharles R. Conway
Charles R. Conway
Nitrous oxide at 50% inhaled concentration has been shown to improve depressive symptoms in patients with treatment-resistant major depression (TRMD). Whether a lower concentration of 25% nitrous oxide provides similar efficacy and persistence of antidepressant effects while reducing the risk of adverse side effects is unknown. In this phase 2 clinical trial (NCT03283670), 24 patients with severe TRMD were randomly assigned in a crossover fashion to three treatments consisting of a single 1-hour inhalation with (i) 50% nitrous oxide, (ii) 25% nitrous oxide, or (iii) placebo (air/oxygen). The primary outcome was the change on the Hamilton Depression Rating Scale (HDRS-21). Whereas nitrous oxide significantly improved depressive symptoms versus placebo (P = 0.01), there was no difference between 25 and 50% nitrous oxide (P = 0.58). The estimated differences between 25% and placebo were −0.75 points on the HDRS-21 at 2 hours (P = 0.73), −1.41 points at 24 hours (P = 0.52), −4.35 points at week 1 (P = 0.05), and −5.19 points at week 2 (P = 0.02), and the estimated differences between 50% and placebo were −0.87 points at 2 hours (P = 0.69), −1.93 points at 24 hours (P = 0.37), −2.44 points at week 1 (P = 0.25), and −7.00 points at week 2 (P = 0.001). Adverse events declined substantially with dose (P < 0.001). These results suggest that 25% nitrous oxide has comparable efficacy to 50% nitrous oxide in improving TRMD but with a markedly lower rate of adverse effects.